Brokerages Set Celcuity, Inc. (NASDAQ:CELC) Price Target at $108.63

Celcuity, Inc. (NASDAQ:CELC) has earned a consensus rating of “Moderate Buy” from the ten ratings firms that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and eight have issued a buy recommendation on the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $108.6250.

Several brokerages have issued reports on CELC. Wells Fargo & Company began coverage on shares of Celcuity in a research report on Friday, December 12th. They set an “overweight” rating and a $126.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celcuity in a research report on Wednesday, January 21st. Jefferies Financial Group lifted their price target on Celcuity from $108.00 to $134.00 and gave the stock a “buy” rating in a report on Tuesday, December 2nd. Needham & Company LLC restated a “buy” rating and issued a $122.00 price target on shares of Celcuity in a research note on Tuesday, March 17th. Finally, Wolfe Research reaffirmed an “outperform” rating and issued a $110.00 price objective on shares of Celcuity in a report on Thursday, March 12th.

Celcuity Stock Performance

NASDAQ CELC opened at $106.04 on Monday. The stock has a market cap of $4.91 billion, a PE ratio of -28.89 and a beta of 0.38. The company has a debt-to-equity ratio of 2.74, a quick ratio of 12.26 and a current ratio of 12.26. The firm has a 50-day moving average of $109.40 and a 200-day moving average of $89.43. Celcuity has a 52-week low of $7.57 and a 52-week high of $120.32.

Insider Buying and Selling at Celcuity

In other news, Director David Dalvey sold 20,000 shares of the business’s stock in a transaction dated Tuesday, January 27th. The shares were sold at an average price of $120.03, for a total value of $2,400,600.00. Following the completion of the sale, the director owned 90,000 shares of the company’s stock, valued at approximately $10,802,700. The trade was a 18.18% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 15.78% of the company’s stock.

Hedge Funds Weigh In On Celcuity

A number of hedge funds have recently bought and sold shares of the business. EverSource Wealth Advisors LLC boosted its holdings in Celcuity by 1,329.2% in the 4th quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company’s stock valued at $34,000 after purchasing an additional 319 shares during the period. Meeder Asset Management Inc. bought a new position in shares of Celcuity during the fourth quarter worth approximately $42,000. Ogorek Anthony Joseph NY ADV acquired a new stake in shares of Celcuity in the third quarter valued at approximately $27,000. US Bancorp DE raised its position in shares of Celcuity by 25.4% in the third quarter. US Bancorp DE now owns 706 shares of the company’s stock valued at $35,000 after buying an additional 143 shares in the last quarter. Finally, NBC Securities Inc. bought a new stake in shares of Celcuity in the fourth quarter valued at approximately $99,000. 63.33% of the stock is owned by institutional investors.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.